Taken together, the data identify JAK2 as a conserved major signal transduction mechanism involved in CXCL12 signaling in B-CLL and suggest that inhibition of JAK PTKs could be a new valuable pharmacological approach to B-CLL therapy. The gene discussed is CXCL12; the disease is B-cell chronic lymphocytic leukemia.